Contrary to the prevailing wisdom of staying private as long as possible, VC Keith Rabois counsels his portfolio companies to pursue an IPO once they hit ~$50 million in predictable revenue. He believes the benefits of being public outweigh the costs much earlier than most founders think.

Biotech leaders often fixate on share price after an IPO, but trading volume is the more important metric for long-term health. High liquidity attracts institutional investors and makes it easier to raise future capital. A stock that "trades by appointment" due to low volume signals a lack of interest and severely limits a company's financial options.

Timing a key data readout is critical for a newly public biotech. A readout in under three months is too soon, as investors will simply wait for the results before buying. Waiting longer than a year risks losing market relevance. The optimal window to maintain momentum is 6-12 months post-IPO.

For late-stage startups, securing a pre-IPO round led by a premier public market investor like Fidelity is a strategic move. It provides more than capital; it offers a crucial stamp of approval that builds significant confidence and credibility with Wall Street ahead of an IPO.

Astute biotech leaders leverage the tension between public financing and strategic pharma partnerships. When public markets are down, pursue pharma deals as a better source of capital. Conversely, use the threat of a public offering to negotiate more favorable terms in pharma deals, treating them as interchangeable capital sources.

A biotech investor's role mirrors that of a record producer by identifying brilliant talent (scientists) who may lack commercial experience. The investor provides the capital, structure, and guidance needed to translate raw scientific innovation into a commercially successful product.

When founders invest their own money, it signals an unparalleled level of commitment and belief. This act serves as a powerful 'magnetic pull,' de-risking the opportunity in the eyes of external investors and making them significantly more likely to commit their own capital.

Unlike in tech where an IPO is often a liquidity event for early investors, a biotech IPO is an "entrance." It functions as a financing round to bring in public market capital needed for expensive late-stage trials. The true exit for investors is typically a future acquisition.

An IPO is not a final exit but the start of a public "marriage" with new responsibilities. This mindset shifts focus from the event itself to rigorously preparing the company for the long-term demands of public markets, for instance through simulated earnings calls and disciplined share allocation to long-term investors.